Umbilical vein and placental vessels from newborns with hereditary haemorrhagic telangiectasia type 1 genotype are normal despite reduced expression of endoglin
- PMID: 14972453
- DOI: 10.1016/S0143-4004(03)00181-4
Umbilical vein and placental vessels from newborns with hereditary haemorrhagic telangiectasia type 1 genotype are normal despite reduced expression of endoglin
Abstract
Hereditary haemorrhagic telangiectasia, HHT, is an autosomal dominant disorder that affects approximately 1 in 8000 people. HHT1 is associated with mutations in the ENG (Endoglin) gene and with haploinsufficiency. The disorder is characterized by focally dilated vessels, which can lead to arteriovenous malformations and serious complications even in young children. In the current study, umbilical cord and placenta samples from newborns with ENG mutations were analyzed to estimate the level of corresponding protein and look for potential vascular dysplasia. We confirmed, using metabolic labelling and flow cytometry, that endoglin levels were significantly reduced to median values of 47 per cent (range 32-56 per cent) and 58 per cent (46-90 per cent), respectively, in human umbilical vein endothelial cells derived from newborns with ENG mutations (HHT1 group; n=18) relative to samples from newborns shown not to have the familial mutation (non-HHT group). We also quantified the relative expression of endoglin by estimating the endoglin/PECAM-1 staining ratio in tissue sections. We observed significantly lower values in the HHT1 group, compared to the non-HHT group for the umbilical vein (n=9; median 0.6 vs 0.9; ranges 0.2-1.0 and 0.5-1.5) and for placental stem villus vessels (n=9 and 10; median 0.42 vs 0.93; ranges 0.24-0.58 and 0.56-1.18). No differences in the estimated umbilical vein cross-sectional area and in the proportion of vessels present in placental villi were observed in sections from the HHT1 group relative to the non-HHT group. Thus, blood vessels from HHT1 individuals are maintained intact in the umbilical vein and placenta during pregnancy and delivery, despite a significant reduction in endoglin expression.
Similar articles
-
Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1.Am J Pathol. 2000 Mar;156(3):911-23. doi: 10.1016/S0002-9440(10)64960-7. Am J Pathol. 2000. PMID: 10702408 Free PMC article.
-
Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin.Pediatr Res. 2000 Jan;47(1):24-35. doi: 10.1203/00006450-200001000-00008. Pediatr Res. 2000. PMID: 10625079
-
Reduced endothelial secretion and plasma levels of transforming growth factor-beta1 in patients with hereditary hemorrhagic telangiectasia type 1.Cardiovasc Res. 2005 Oct 1;68(1):155-64. doi: 10.1016/j.cardiores.2005.04.028. Cardiovasc Res. 2005. PMID: 15907823
-
Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia.Trends Cardiovasc Med. 2000 Oct;10(7):279-85. doi: 10.1016/s1050-1738(01)00062-7. Trends Cardiovasc Med. 2000. PMID: 11343967 Review.
-
Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease.J Med Genet. 2006 Feb;43(2):97-110. doi: 10.1136/jmg.2005.030833. Epub 2005 May 6. J Med Genet. 2006. PMID: 15879500 Free PMC article. Review.
Cited by
-
Vascular defects associated with hereditary hemorrhagic telangiectasia revealed in patient-derived isogenic iPSCs in 3D vessels on chip.Stem Cell Reports. 2022 Jul 12;17(7):1536-1545. doi: 10.1016/j.stemcr.2022.05.022. Epub 2022 Jun 30. Stem Cell Reports. 2022. PMID: 35777360 Free PMC article.
-
Markers for characterization of bone marrow multipotential stromal cells.Stem Cells Int. 2012;2012:975871. doi: 10.1155/2012/975871. Epub 2012 May 14. Stem Cells Int. 2012. PMID: 22666272 Free PMC article.
-
Immunohistochemical analysis of a merkeloma observed in a patient affected by hereditary haemorrhagic telangiectasia.BMJ Case Rep. 2010;2010:bcr09.2009.2251. doi: 10.1136/bcr.09.2009.2251. Epub 2010 Feb 8. BMJ Case Rep. 2010. PMID: 22315638 Free PMC article.
-
Engineered bone marrow mesenchymal stem cell-derived exosomes loaded with miR302 through the cardiomyocyte specific peptide can reduce myocardial ischemia and reperfusion (I/R) injury.J Transl Med. 2024 Feb 17;22(1):168. doi: 10.1186/s12967-024-04981-7. J Transl Med. 2024. PMID: 38368334 Free PMC article.
-
Employment of diverse in vitro systems for analyzing multiple aspects of disease, hereditary hemorrhagic telangiectasia (HHT).Cell Biosci. 2024 May 22;14(1):65. doi: 10.1186/s13578-024-01247-z. Cell Biosci. 2024. PMID: 38778363 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources